Autopsy report · NCT00692458

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

“Withdrawn for administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

Comparator: odanacatib; Comparator: placebo

Participants

0

Trials that died the same way

• MAGIK for Femoral/Tibial Shaft Fractures
  “Withdrawn due to lack of funding.” (77% match in meaning)
• Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
  “Withdrawn due to lack of resources” (76% match in meaning)
• Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
  “Withdrawn due to low accrual” (76% match in meaning)
• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
  “Withdrawn due to poor accrual” (75% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.